A MANAGED LONGEVITY PROGRAMME
A physician. A daily AI. A protocol built around your biology — not a generic template. This is what managed longevity looks like.
A programme catered to the exclusive few.
Launching late 2026
THE MOMENT
On March 20, Novo Nordisk's Indian semaglutide patent expired. Over 50 generic brands entered the market overnight. A drug that cost ₹16,000 a month became available for ₹1,800. 101 million Indians live with diabetes. 351 million have abdominal obesity. The therapy is now within reach. The clinical management layer still does not exist.
The drugs work. The management layer does not exist. That is what YouLabs — and 150 — are building.
101M
Indians with diabetes
351M
with abdominal obesity
50+
generic brands entered this week
THE PROBLEM
Patients start powerful new therapies and are sent home with no follow-up protocol.
Symptoms, side effects, and medication adherence go unrecorded between visits.
Each consultation starts from scratch. No trend analysis. No pattern recognition.
When something goes wrong, patients wait for the next appointment — or go to the ER.
40% of patients experience adverse effects in the first weeks without clinical management. 25–40% of weight lost on incretin therapy is lean muscle, not fat. Nobody tracks this.
THE INSIGHT
Fix metabolism — and the body begins to fix itself. The heart. The kidneys. The liver. The joints. The brain. The reward system. This is what the science now shows. And it is why a managed longevity programme starts here.
FDA-approved indications for incretin therapy as of 2025. Six conditions. One drug class. Zero management infrastructure in India.
THE SOLUTION
Physical clinics. A daily AI. Proprietary therapeutics. The clinical management layer that did not exist — until now.
Physical clinics. Vascular diagnostics. Body composition. The data no app can replicate.
Daily check-ins. Bloodwork trends. Physician escalation. WhatsApp-native. No download.
13 proprietary formulations. Incretin therapy. Peptide protocols. Own-brand pharma roadmap.
WHAT YOU GET
150 — THE AI
Not a chatbot. Not a wellness app. A clinical AI that knows your full history and acts on it.
WHY THIS WORKS
Every protocol is physician-directed. AI assists — it does not prescribe. Clinical oversight at every step.
We track trends across months and years, not snapshots. Patterns emerge. Interventions improve.
No app to download. No new behaviour to learn. Patients engage on the platform they already use, every day.
Annual memberships only. This filters for patients who are serious about their health — and improves outcomes.
India manufactures 20% of the world's generic pharmaceuticals. Dr. Apurba Ganguly — 30 years of vascular research, 120+ published studies, 13 proprietary formulations. Peptides sourced from Bachem Switzerland, Indena Italy, MIT-developed formulations. World-class ingredients. India pricing.
THE PLATFORM
Physical clinics. Vascular diagnostics. Body composition. The data no app can replicate.
Daily check-ins. Bloodwork trends. Physician escalation. WhatsApp-native. No download.
13 proprietary formulations. Incretin therapy. Peptide protocols. Own-brand pharma roadmap.
Annual memberships. Diagnostics. Products. Five revenue streams per patient.
Every interaction builds a continuous care system.
CLINICAL EVIDENCE
PUBLISHED SCIENCE
The clinical trials that define the standard of care 150 is built on.
JOIN THE WAITLIST
A programme catered to the exclusive few.
We review every application personally. Currently accepting members in Bangalore, Delhi, Hyderabad, and Mumbai.
We are building the system that continues it.
A programme designed for 150.
Bangalore · Delhi · Hyderabad · Mumbai